Group 1 - The core viewpoint of the articles highlights the performance and market position of Shenzhen New Industry Biomedical Engineering Co., Ltd. in the medical device sector, particularly in the in vitro diagnostics field [1][2] - As of August 15, the company's stock closed at 58.85 yuan, with a PE ratio of 25.13, marking a 46-day low, and a total market capitalization of 46.24 billion yuan [1] - The average PE ratio for the medical device industry is 56.58, with a median of 39.97, placing the company at the 50th position within the industry [1][2] Group 2 - The company reported a 2025 Q1 revenue of 1.125 billion yuan, reflecting a year-on-year increase of 10.12%, and a net profit of 438 million yuan, up 2.65% year-on-year, with a gross margin of 68.01% [1] - As of March 31, 2025, the number of shareholders increased to 19,269, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1] - The company has received accolades such as the "National Brand Gold Award" for medical equipment in 2024, indicating high customer satisfaction and service quality, particularly in tertiary hospitals [1]

（文章来源：每日经济新闻） 2024年1至12月份，新产业的营业收入构成为：体外诊断占比99.82%，其他业务占比0.18%。 新产业（SZ 300832，收盘价：58.85元）8月15日晚间发布公告称，近日，深圳市新产业生物医学工程 股份有限公司收到了广东省药品监督管理局颁发的1项《医疗器械注册证》。产品名称为"全自动凝血分 析仪"。 ...

证券代码：300832 证券简称：新产业 公告编号：2025-061 深圳市新产业生物医学工程股份有限公司 关于获得医疗器械注册证的公告 二、对公司的影响及风险提示 本次拿证的 Hemolumi H6 全自动凝血分析仪采用光学和磁珠法双方法学设 计，检测准确度高、速度快、抗干扰性强；内置溶血、黄疸和乳糜（HIL）样本 指数检测，可对异常样本提前预检，有效降低医疗误诊情况；所有耗材均具备 余量指示功能，支持不停机连续加载；采用模块化设计，可连入全实验室自动 化系统。 上述医疗器械注册证的取得，丰富了公司凝血分析仪器产品线，将对公司 发展具有正面影响，但对近期的生产经营和业绩不会产生重大影响，敬请投资 者给予关注并注意投资风险。 特此公告。 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 近日，深圳市新产业生物医学工程股份有限公司（以下简称"公司"）收 到了广东省药品监督管理局颁发的 1 项《医疗器械注册证》。具体情况如下： 一、医疗器械注册证的具体情况 | 产品名称 | 及型号 | | 注册 分类 | 注册证编号 | | | 注册证有效期 | | | 适用范围 ...

Core Viewpoint - The company has recently received two invention patent certificates from the National Intellectual Property Administration and the Japan Patent Office, indicating advancements in its technology related to sample analysis and nucleic acid testing [1] Group 1 - The company announced the receipt of an invention patent certificate for a reagent dispensing device and a sample analysis instrument [1] - The company also received a patent for a substance extraction device and a nucleic acid testing integrated machine [1]

Core Viewpoint - The company has recently received two invention patent certificates from the National Intellectual Property Administration of China and the Japan Patent Office, indicating advancements in its technology and potential for future growth in the biomedical field [2] Company Summary - Shenzhen New Industry Biomedical Engineering Co., Ltd. announced the receipt of two invention patents, titled "Reagent Injection Device and Sample Analyzer with It" and "Test Substance Extraction Device and Nucleic Acid Detection Integrated Machine" [2] - For the fiscal year 2024, the company's revenue composition is heavily weighted towards in vitro diagnostics, accounting for 99.82% of total revenue, while other business segments contribute only 0.18% [2]

证券代码：300832 证券简称：新产业 公告编号：2025-060 深圳市新产业生物医学工程股份有限公司 关于公司获得发明专利证书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 深圳市新产业生物医学工程股份有限公司（以下简称"公司"）于近日收到 1项国家知识产权局、1项日本特许厅颁发的《发明专利证书》，现将本次取得的 发明专利具体情况公告如下： 1、发明名称：试剂加注装置及具有其的样本分析仪 中国专利号：ZL202011642583.X 授权公告日：2025年08月05日 上述专利保护技术为公司自主研发，本发明应用于公司全自动生化分析仪 Biossays C8，提供了一种试剂加注装置，该装置通过组合设计水平转动组件、竖 直升降组件和多个悬臂组件，并利用高低错位及长短臂结构集中布置多个悬臂组 件，使各悬臂组件均能到达试剂盘的内外圈吸取试剂且互不干扰，从而显著减小 了装置的空间占用率，提高了运行效率。 2、发明名称：待测物提取装置及具有其的核酸检测一体机 日本专利号：特许第7721622号 专利权人：深圳市新产业生物医学工程股份有限公司 发明人：饶捷、尹 ...

Core Viewpoint - The China Securities Index for Healthcare Equipment and Services has shown significant growth, with a 9.79% increase over the past month and a 13.13% increase over the past three months, indicating a strong performance in the healthcare sector [1]. Group 1: Index Performance - The China Securities Index for Healthcare Equipment and Services rose by 0.76% to 15,136.64 points, with a trading volume of 38.83 billion yuan [1]. - Year-to-date, the index has increased by 9.74% [1]. Group 2: Index Composition - The index is composed of listed companies in the healthcare sector, reflecting the overall performance of these companies [1]. - The top ten weighted companies in the index include: - Mindray Medical (9.04%) - United Imaging (7.59%) - Aier Eye Hospital (7.05%) - Aimeike (3.3%) - Huatai Medical (2.95%) - Lepu Medical (2.79%) - New Industry (2.64%) - Yuyue Medical (2.52%) - Meinian Onehealth (1.93%) - Yingke Medical (1.92%) [1]. Group 3: Market Distribution - The index's holdings are primarily listed on the Shenzhen Stock Exchange (59.62%) and the Shanghai Stock Exchange (40.38%) [1]. - The healthcare sector accounts for 100% of the index's holdings [1]. Group 4: Index Adjustment and Fund Tracking - The index samples are adjusted biannually, with adjustments occurring on the next trading day after the second Friday of June and December [2]. - Public funds tracking the healthcare index include various Southern and Tianhong funds, as well as ETFs from multiple financial institutions [2].

Group 1: Energy Transition - The World Economic Forum's 16th Annual Meeting of New Champions focused on energy transition, with discussions on topics such as "current status of energy transition" and "China's role in global energy transition" [2][5] - The average cost of electricity from wind and solar projects has significantly decreased, largely due to contributions from China [5] - China's production of new energy vehicles is expected to grow by over 40% year-on-year [5] Group 2: New Industry Upgrades - Artificial intelligence was a major focus at the forum, with numerous discussions on topics like "AI+ era" and "generative AI accelerating clinical research" [6] - Schneider Electric reported a 15.9% reduction in energy consumption in its supply chain in China compared to 2019, highlighting the impact of digital technology and lean management [7][8] Group 3: Emerging Technologies - The forum released a list of the top ten emerging technologies for 2025, reflecting trends in trust and security, sustainable industries, human health, and energy-material integration [11] - New technologies showcased included bionic dexterous hands and virtual human interaction machines, emphasizing advancements in AI and biotechnology [10][13]

Group 1 - The core viewpoint is that the medical device sector is experiencing a strong performance, with notable increases in stock prices for companies like Lepu Medical, Mindray, and United Imaging, indicating a positive market trend [1][2] - Medical-related ETFs have also seen a rise of approximately 2%, reflecting the overall strength of the sector [1][2] - Analysts suggest that increasing internationalization will provide more investment opportunities in the medical device sector, with several companies expected to achieve high growth in international business by 2025 [2] Group 2 - The performance of Hong Kong's medical device stocks has been strong this year, which is anticipated to influence the A-share market positively [2] - The investment opportunities in both A-share and Hong Kong medical device sectors are expected to continue to be prominent [2]

Group 1 - The establishment of Suzhou Jialin Equity Investment Partnership (Limited Partnership) with a capital contribution of 300 million yuan [1] - The business scope includes equity investment and venture capital, specifically limited to investments in unlisted companies [1] - The company is co-funded by Suzhou Innovation Industry Development Guidance Phase II Fund Partnership (Limited Partnership) among others [1]